Postoperative scars after sub-brow blepharoplasty
Conditions
Interventions
Peri-incisional injection of botulinum toxin type A after sub-brow blepharoplasty.
Peri-incisional injection of an equal volume of normal saline on the contralateral side as placebo control.
Sponsors
Oculofacial Clinic Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 18 years or older who are scheduled to undergo bilateral sub-brow blepharoplasty, are eligible for split-scar comparison, are able to complete postoperative follow-up for 6 months, and provide written informed consent after receiving a full explanation of the study.
Exclusion criteria
Exclusion criteria: Patients with a history of hypersensitivity or allergy to botulinum toxin type A preparations Patients with neuromuscular junction disorders, such as myasthenia gravis or Lambert Eaton syndrome Patients with systemic diseases that may affect wound healing Patients with a history of keloid formation or hypertrophic scarring Pregnant or breastfeeding women, or women who may be pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in scar width between the botulinum toxin type A-treated side and the untreated side at 6 months postoperatively | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative scar erythema Postoperative scar firmness Postoperative scar elevation POSAS score Vancouver Scar Scale (VSS) Patient satisfaction Evaluator satisfaction Adverse events (e.g., ptosis, asymmetry, facial expression disturbance) Delayed wound healing Surgical site infection | — |
Countries
Japan
Contacts
Public ContactSaori Kotaki
Oculofacial Clinic Tokyo Department of Ophthalmology
Outcome results
None listed